BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic vertebral tumor misdiagnosed in magnetic resonance imaging as benign degenerative bone marrow changes: a case report.

We report a man with low back and right groin pain as a result of metastatic breast carcinoma which was misdiagnosed in magnetic resonance imaging as benign degenerative changes.

[MeSH-major] Adenocarcinoma / secondary. Bone Marrow / pathology. Bone Neoplasms / secondary. Breast Neoplasms, Male / pathology. Diagnostic Errors. Lumbar Vertebrae / pathology. Magnetic Resonance Imaging

[MeSH-minor] Humans. Low Back Pain / etiology. Male. Middle Aged. Radiography. Radionuclide Imaging

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiology. 1985 Oct;157(1):157-66 [3875878.001]

[Cites] Clin Nucl Med. 2000 Aug;25(8):647-9 [10944033.001]

[Cites] Radiology. 1988 Jan;166(1 Pt 1):193-9 [3336678.001]

[Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]

[Cites] Cancer. 1987 Mar 15;59(6):1112-6 [3815285.001]

[Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Dec 25;52(12):1611-9 [1488288.001]

[Cites] AJR Am J Roentgenol. 1990 Jul;155(1):85-8 [2112871.001]

(PMID = 15449024.001).

[ISSN] 0172-8172

[Journal-full-title] Rheumatology international

[ISO-abbreviation] Rheumatol. Int.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.

The spectrum of breast lesions in children and adolescents varies markedly from that for adults, with the former lesions being overwhelmingly benign.

A breast mass in a young boy or girl may arise from normal and abnormal breast development.

After onset of puberty, most cases of breast enlargement arise from benign fibroadenoma in girls and gynecomastia in boys.

These conditions have specific imaging appearances, although juvenile (often giant) fibroadenoma cannot be distinguished from phyllodes tumor, which can be benign or malignant.

A diagnosis of juvenile papillomatosis (a benign lesion) portends later development of breast cancer, and patients with this condition should be closely monitored.

Malignant lesions of the breast in children are rare.

The most common primary breast malignancy is malignant phyllodes tumor.

Primary breast carcinoma is exceedingly rare in the pediatric age group, but its imaging appearance in children is the same as seen in adults and is different from that of almost all benign lesions.

In girls, diagnostic interventions may injure the developing breast and cause subsequent disfigurement.

Given this risk and the low prevalence of malignant disease in this population, a prudent course should be followed in the diagnosis of breast lesions.

[MeSH-major] Breast Diseases / radiography

[MeSH-minor] Adolescent. Breast / abnormalities. Breast / anatomy & histology. Breast / growth & development. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Child. Child, Preschool. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fibroadenoma / radiography. Granular Cell Tumor / diagnosis. Granular Cell Tumor / pathology. Granular Cell Tumor / radiography. Gynecomastia / pathology. Gynecomastia / radiography. Humans. Infant. Infant, Newborn. Male. Nipples / abnormalities. Papilloma / diagnosis. Papilloma / pathology. Papilloma / radiography. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology. Phyllodes Tumor / radiography. Puberty. Puberty, Precocious / diagnosis. Young Adult

MedlinePlus Health Information. consumer health - Breast Diseases.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19448124.001).

[ISSN] 1527-1323

[Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc

[ISO-abbreviation] Radiographics

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 90

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.

We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.

EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.

A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).

Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).

Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.

CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.

[MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood

[MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16951234.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Forced expression of Cks1 and Cks2 in benign prostate tumor epithelial cells promoted cell population growth.

Knockdown of Cks1 expression in malignant prostate tumor cells inhibited proliferation, anchorage-independent growth, and migration activities, whereas knockdown of Cks2 expression induced programmed cell death and inhibited the tumorigenicity.

Collectively, the data suggest that elevated expression of Cks1 contributes to the tumorigenicity of prostate tumor cells by promoting cell growth and elevated expression of Cks2 protects the cells from apoptosis.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oral Oncol. 2005 Feb;41(2):105-16 [15695111.001]

[Cites] Mol Gen Genet. 1986 Feb;202(2):291-3 [3010051.001]

[Cites] Mol Cell Biol. 1989 May;9(5):2034-41 [2664468.001]

[Cites] Genes Dev. 1990 Aug;4(8):1332-44 [2227411.001]

[Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]

[Cites] Cancer Res. 1997 Dec 1;57(23):5369-78 [9393762.001]

[Cites] Prog Nucleic Acid Res Mol Biol. 1998;59:135-76 [9427842.001]

[Cites] Int J Cancer. 1999 Jul 2;82(1):98-104 [10360827.001]

[Cites] Am J Pathol. 2004 Dec;165(6):2147-55 [15579456.001]

[Cites] J Biol Chem. 2004 Dec 31;279(53):55348-54 [15513912.001]

[Cites] Cancer Cell. 2005 Jan;7(1):51-63 [15652749.001]

[Cites] Oncogene. 2006 Jan 12;25(2):310-6 [16116475.001]

[Cites] Int J Cancer. 2006 May 15;118(10):2461-9 [16353136.001]

[Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]

[Cites] Genes Dev. 2006 Jun 1;20(11):1511-24 [16705040.001]

[Cites] Oncol Rep. 2006 Sep;16(3):521-31 [16865252.001]

[Cites] Cancer. 2006 Aug 15;107(4):668-75 [16826582.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9986-94 [17047061.001]

[Cites] J Urol. 2006 Nov;176(5):2285-9 [17070313.001]

[Cites] Int J Oncol. 2006 Dec;29(6):1337-47 [17088971.001]

[Cites] J Biol Chem. 2007 Jan 5;282(1):390-6 [17092932.001]

[Cites] Development. 2007 Feb;134(4):723-34 [17215304.001]

[Cites] FEBS Lett. 2007 Mar 20;581(6):1166-72 [17336302.001]

[Cites] Mod Pathol. 2007 Apr;20(4):497-507 [17384652.001]

[Cites] Breast Cancer Res. 2007;9(2):R25 [17428314.001]

[Cites] Cancer. 2005 Apr 1;103(7):1336-46 [15717322.001]

[Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]

[Cites] Br J Cancer. 2005 Jun 20;92(12):2249-61 [15900300.001]

[Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]

[Cites] Oncogene. 2005 Aug 4;24(33):5246-51 [15897880.001]

[Cites] Breast Cancer Res. 2005;7(5):R737-44 [16168119.001]

[Cites] Nat Cell Biol. 2006 Jan;8(1):17-26 [16341208.001]

[Cites] Exp Cell Res. 2001 Mar 10;264(1):148-68 [11237531.001]

[Cites] Nat Cell Biol. 2001 Mar;3(3):321-4 [11231585.001]

[Cites] Mol Cell. 2001 Mar;7(3):639-50 [11463388.001]

[Cites] Semin Cancer Biol. 2003 Feb;13(1):41-7 [12507555.001]

[Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]

[Cites] Cell Cycle. 2003 Jan-Feb;2(1):59-63 [12695690.001]

[Cites] Science. 2003 Apr 25;300(5619):647-50 [12714746.001]

[Cites] Cancer Res. 2003 Aug 15;63(16):4936-44 [12941818.001]

[Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]

[Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]

[Cites] Lab Invest. 2004 May;84(5):588-96 [15064772.001]

[Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]

[Cites] EMBO J. 1987 Nov;6(11):3507-14 [3322810.001]

(PMID = 18498131.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA096824-01A1; United States / NCI NIH HHS / CA / R01 CA096824-01A1; United States / NCI NIH HHS / CA / CA096824-05; United States / NCI NIH HHS / CA / R01 CA096824-05; United States / NCI NIH HHS / CA / R56 CA096824; United States / NCI NIH HHS / CA / CA096824; United States / NCI NIH HHS / CA / R01 CA096824

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / CKS1B protein, human; 0 / CKS2 protein, human; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDC28 Protein Kinase, S cerevisiae; EC 2.7.11.22 / Cks1 protein, mouse; EC 2.7.11.22 / Cks2 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinases

[Other-IDs] NLM/ NIHMS93124; NLM/ PMC3262990

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: One hundred patients with histologically confirmed malignant or benign hepatic tumor (maximum size 5 cm) were analyzed.

The cut-off of the gray value differences between tumor and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.

RESULTS: One hundred patients with 59 malignant (43 colon, 5 breast, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41 benign (15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.

The late venous phase proved to be the most sensitive for classification of the tumor type.

Of the 41 benign tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Germany. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Angiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prospective Studies. ROC Curve. Reproducibility of Results. Sensitivity and Specificity. Time Factors. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - Liver Cancer.

Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18081224.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study

[Publication-country] China

[Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride

[Other-IDs] NLM/ PMC4205454

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE: Married (vs. unmarried) individuals have improved health status and longer life expectancies in a variety of benign and malignant disease states, including prostate, breast, head/neck, and lung cancers.

Married individuals (vs. unmarried) were more often male (84 vs. 62%) and had a higher BMI (28.1 vs. 25.9).

These findings may support the evidence (observed in other tumor types and other disease states) that married persons present earlier than unmarried individuals, and this may help explain the improved survival outcomes that have been observed in married patients with bladder cancer.

[MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Marital Status. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

[MeSH-minor] Aged. Cohort Studies. Creatinine / blood. Female. Follow-Up Studies. Hematocrit. Humans. Length of Stay. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Bladder cancer.

MedlinePlus Health Information. consumer health - Bladder Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 2005 Sep 15;104(6):1188-94 [16078264.001]

[Cites] Soc Sci Med. 2003 Dec;57(11):2137-47 [14512244.001]

[Cites] Psychooncology. 2008 Sep;17(9):869-76 [18033697.001]

[Cites] J Urol. 1996 Nov;156(5):1696-70 [8863573.001]

[Cites] Ann Epidemiol. 2000 May;10(4):224-38 [10854957.001]

[Cites] Health Psychol. 1988;7(3):269-97 [3289916.001]

[Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]

[Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]

[Cites] World J Surg. 2003 Mar;27(3):304-8 [12607056.001]

[Cites] Am J Epidemiol. 1982 Jul;116(1):123-40 [7102648.001]

(PMID = 19219612.001).

[ISSN] 1433-8726

[Journal-full-title] World journal of urology

[ISO-abbreviation] World J Urol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] AYI8EX34EU / Creatinine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.

BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases.

Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM.

PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion).

Mann-Whitney analysis was used to compare SMRP values according to the etiology of the effusion.

RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02).

CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.

[MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Hematologic Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis

[MeSH-minor] Biomarkers. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Male. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Mesothelioma.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19783262.001).

[ISSN] 0025-7753

[Journal-full-title] Medicina clínica

[ISO-abbreviation] Med Clin (Barc)

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Biomarkers; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

They are usually benign, but as they are infrequently diagnosed preoperatively, they may be confused clinically with malignant lesions.

Of these, 99patients were female and 23 male, providing a male:female ratio of l to 4.3.

Lesions ranged in size from 0.2 cm to 10 cm in greatest dimension, the average size being 1.85 cm and were found in a diverse array of anatomic locations, the most common being the vulva, breast and tongue.

The correct clinical diagnosis was proffered preoperatively in only one case.

In contrast, a malignant diagnosis was suggested in 19 cases.

In particular lesions of the tongue accounted for fewer than expected, while lesions of the breast and vulva were considerably increased.

[MeSH-major] Granular Cell Tumor / epidemiology. Granular Cell Tumor / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn. Male. Middle Aged. Tongue Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology. West Indies / epidemiology. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21866599.001).

[ISSN] 0043-3144

[Journal-full-title] The West Indian medical journal

[ISO-abbreviation] West Indian Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Jamaica

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.

The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.

The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.

This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.

Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. PROGESTERONE .

Hazardous Substances Data Bank. CYCLOHEXIMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]

[Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]

[Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]

[Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]

[Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]

[Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]

[Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]

[Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]

[Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]

[Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]

[Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]

[Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]

[Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]

[Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]

[Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]

[Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]

[Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]

[Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]

[Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]

[Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]

[Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]

[Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]

[Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]

[Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]

[Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]

[Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]

[Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]

[Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]

[Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]

[Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]

[Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]

[Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]

[Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]

[Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]

[Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]

[Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]

[Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]

[Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]

[Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]

[Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]

[Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]

[Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]

[Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]

[Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]

[Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]

[Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]

[Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]

[Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]

[Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]

(PMID = 19690070.001).

[ISSN] 1522-1555

[Journal-full-title] American journal of physiology. Endocrinology and metabolism

[ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: Prostatic stromal hyperplasia with atypia consists of 1 or more ill-defined, uncircumscribed, hyperplastic stromal nodules, with variable numbers of atypical, bizarre giant cells, with vacuolated nuclei, smudged chromatin, and frequent multinucleation infiltrating around benign acini.

CONCLUSIONS: Prostatic stromal hyperplasia with atypia is a rare, benign lesion, composed of degenerative myocytes with atypia that is histologically and clinically reminiscent of benign counterparts in the myometrium, breast, vulva, vagina, and elsewhere.

Recognition of this distinctive entity should allow separation from phyllodes tumor and sarcoma of the prostate.

The phrase stromal tumor of uncertain malignant potential is inappropriate for this benign tumor, and its use is discouraged.

[MeSH-major] Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Stromal Cells / pathology

[MeSH-minor] Aged. Aged, 80 and over. Cell Nucleus / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Muscle Cells / metabolism. Muscle Cells / pathology. Receptors, Androgen / metabolism. Retrospective Studies. Vimentin / metabolism

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18976007.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Androgen; 0 / Vimentin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Granular cell tumour of the male breast.

Granular cell tumour (GCT) is a rare neoplasm that can be found in multiple sites throughout the body.

Occasionally GCT is located in the breast.

In general, it appears as a singular benign lesion, although it can be multi-focal and rare cases with malignant behaviour have been reported.

We report a rare case of granular cell tumour of the nipple in the male breast, treated by wide local excision.

[MeSH-major] Breast Neoplasms, Male / surgery. Granular Cell Tumor / surgery

[MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Nipples

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18411585.001).

[ISSN] 0001-5458

[Journal-full-title] Acta chirurgica Belgica

[ISO-abbreviation] Acta Chir. Belg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Belgium

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Discovering new melanoma biomarkers would improve early detection and diagnosis.

Volatiles released from fresh biopsy tissue of melanoma and benign naevus were compared based on their difference in frequency distribution and their expression level.

MedlinePlus Health Information. consumer health - Birthmarks.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Moles.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anal Chem. 2000 Feb 15;72(4):747-56 [10701259.001]

[Cites] J Am Chem Soc. 2010 Mar 24;132(11):3642-3 [20196537.001]

[Cites] Philos Trans R Soc Lond B Biol Sci. 2002 Jan 29;357(1417):17-23 [11839178.001]

[Cites] Breast J. 2003 May-Jun;9(3):184-91 [12752626.001]

[Cites] Trends Biochem Sci. 2003 Jun;28(6):329-35 [12826405.001]

[Cites] Cancer Treat Rev. 2003 Dec;29(6):489-99 [14585259.001]

[Cites] Lancet. 2004 Feb 28;363(9410):728-30 [15005091.001]

[Cites] Prev Med. 2004 Apr;38(4):382-7 [15020171.001]

[Cites] Environ Health Perspect. 2004 May;112(7):A396-7 [15159211.001]

[Cites] Nat Rev Cancer. 2004 Jul;4(7):551-61 [15229480.001]

[Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):269-77 [15261821.001]

[Cites] Nature. 1966 Nov 26;212(5065):933-5 [4306794.001]

[Cites] J Biol Chem. 1980 Nov 10;255(21):10493-501 [7430132.001]

[Cites] Anticancer Res. 1985 Jan-Feb;5(1):1-30 [3888043.001]

[Cites] Mutat Res. 1989 Jan;219(1):71-9 [2911273.001]

[Cites] Biochem Pharmacol. 1995 Dec 22;50(12):1955-62 [8849320.001]

[Cites] Science. 1996 Jul 5;273(5271):59-63 [8658196.001]

[Cites] J Biol Chem. 1997 May 2;272(18):11895-901 [9115250.001]

[Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2291-8 [10325416.001]

[Cites] Cancer Res. 1999 Aug 15;59(16):3855-60 [10463569.001]

[Cites] J Invest Dermatol. 1964 Aug;43:111-3 [14196302.001]

[Cites] Biochemistry. 2004 Nov 16;43(45):14332-9 [15533037.001]

[Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]

[Cites] J Invest Dermatol. 2006 Dec;126(12):2565-75 [17108903.001]

[Cites] Mass Spectrom Rev. 2007 Jan-Feb;26(1):51-78 [16921475.001]

[Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]

[Cites] Am J Clin Nutr. 2007 Apr;85(4):946-9 [17413090.001]

[Cites] Cancer Biomark. 2007;3(2):95-109 [17522431.001]

[Cites] Int J Epidemiol. 2008 Apr;37 Suppl 1:i23-30 [18381390.001]

[Cites] Skin Res Technol. 2008 May;14(2):226-36 [18412567.001]

[Cites] PLoS Med. 2008 Jun 3;5(6):e120 [18532874.001]

[Cites] J Thorac Oncol. 2008 Jul;3(7):774-80 [18594325.001]

[Cites] Int J Cancer. 2008 Nov 15;123(10):2446-55 [18729182.001]

[Cites] Br J Dermatol. 2008 Sep;159(4):780-91 [18637798.001]

[Cites] J Am Chem Soc. 2008 Oct 29;130(43):14111-3 [18831549.001]

[Cites] Nature. 2008 Oct 23;455(7216):1054-6 [18948945.001]

[Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]

[Cites] Can Fam Physician. 2009 Jan;55(1):24; autor reply 24 [19155361.001]

[Cites] Anal Bioanal Chem. 2009 Feb;393(3):781-95 [18836706.001]

[Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]

[Cites] J Am Soc Mass Spectrom. 2009 Mar;20(3):464-8 [19070510.001]

[Cites] Am J Pathol. 2009 Apr;174(4):1524-33 [19342374.001]

[Cites] Nat Rev Genet. 2009 May;10(5):295-304 [19308066.001]

[Cites] Cancer Control. 2009 Jul;16(3):200-18 [19556960.001]

[Cites] Eur Respir J. 2009 Jul;34(1):261-75 [19567608.001]

[Cites] BMC Cancer. 2009;9:348 [19788722.001]

[Cites] Pigment Cell Melanoma Res. 2009 Dec;22(6):750-60 [19735457.001]

[Cites] Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71 [19788535.001]

[Cites] Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20 [20143319.001]

[Cites] J Invest Dermatol. 2001 Apr;116(4):520-4 [11286617.001]

(PMID = 21079799.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA132046-02; United States / NCI NIH HHS / CA / R21 CA132046; United States / NCI NIH HHS / CA / R21CA 132046; United States / NCI NIH HHS / CA / R21 CA132046-01A1; United States / NCI NIH HHS / CA / R21 CA132046-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Volatile Organic Compounds

[Other-IDs] NLM/ PMC2973952

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.

Our objective was to evaluate features of these foci associated with benign or malignant etiology.

Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time.

The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo).

On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for benign, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for benign, P < 0.01; t test).

Variables associated with benign etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for benign vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test).

CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

Genetic Alliance. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Nucl Med. 2009 Mar;50(3):489-90 [19223415.001]

(PMID = 18765585.001).

[ISSN] 0161-5505

[Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine

[ISO-abbreviation] J. Nucl. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Total endoscopic thyroidectomy with bilateral breast areola and ipsilateral axillary (BBIA) approach.

The present study reviews our experiences with endoscopic thyroidectomy using bilateral breast areola and ipsilateral axillary (BBIA) approach to evaluate its safety and feasibility.

METHODS: From June 2003 through November 2007, the study group was comprised of 68 consecutive patients with benign thyroid nodules (66 women; mean age, 33.28 +/- 10.3 (range, 15-72) years).

RESULTS: The mean maximum diameter of the tumor was 3.14 +/- 1.61 (range, 1-10.7) cm.

[MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Feasibility Studies. Female. Humans. Length of Stay. Male. Middle Aged. Nipples. Retrospective Studies. Treatment Outcome. Young Adult

MedlinePlus Health Information. consumer health - Endoscopy.

MedlinePlus Health Information. consumer health - Thyroid Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Laryngoscope. 2006 Oct;116(10):1745-8 [17003721.001]

[Cites] Thyroid. 2002 Aug;12(8):703-6 [12225638.001]

[Cites] Am J Surg. 2001 Jun;181(6):567-70 [11513788.001]

[Cites] J Surg Oncol. 1998 Nov;69(3):178-80 [9846506.001]

[Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]

[Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]

[Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]

[Cites] Biomed Pharmacother. 2002;56 Suppl 1:68s-71s [12487256.001]

[Cites] World J Surg. 2004 Nov;28(11):1075-8 [15490052.001]

[Cites] J Am Coll Surg. 2003 Feb;196(2):189-95 [12595044.001]

[Cites] Anesth Analg. 2000 Mar;90(3):760-2 [10702471.001]

[Cites] Br J Surg. 1996 Jun;83(6):875 [8696772.001]

[Cites] Surg Laparosc Endosc. 1994 Apr;4(2):92-9 [8180774.001]

[Cites] Biomed Pharmacother. 2002;56 Suppl 1:64s-67s [12487255.001]

[Cites] Surgery. 2000 Dec;128(6):1035-42 [11114640.001]

[Cites] J Am Coll Surg. 2000 Sep;191(3):336-40 [10989910.001]

[Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]

(PMID = 18668282.001).

[ISSN] 0364-2313

[Journal-full-title] World journal of surgery

[ISO-abbreviation] World J Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa).

Mean IL-6 levels were also higher in PCa patients and in patients with benign prostatic hyperplasia (BPH) than in HS while Cyst C resulted significantly higher in PCa but not in BPH patients as compared to HS.

[MeSH-major] Bone Neoplasms / blood. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Cystatin C / blood. Interleukin-6 / blood. Prostatic Neoplasms / pathology

[MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Female. Humans. Imidazoles / therapeutic use. Male. Middle Aged. Osteoporosis / blood. Osteoporosis / complications. Prostate-Specific Antigen / blood. ROC Curve

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Bone. 2005 Nov;37(5):601-6 [16112634.001]

[Cites] Breast Cancer Res Treat. 2007 Apr;102(2):129-35 [16927176.001]

[Cites] Arthritis Res Ther. 2007;9 Suppl 1:S5 [17634144.001]

[Cites] Anticancer Res. 2006 Jan-Feb;26(1A):23-6 [16475674.001]

[Cites] Pathol Res Pract. 2005;200(11-12):753-62 [15792117.001]

[Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]

[Cites] Urology. 2001 Dec;58(6):1008-15 [11744478.001]

[Cites] Bone. 2004 Sep;35(3):689-96 [15336605.001]

[Cites] J Clin Endocrinol Metab. 2001 May;86(5):2032-42 [11344203.001]

[Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):84-9 [10763147.001]

[Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]

[Cites] Biochimie. 2008 Feb;90(2):208-26 [17935853.001]

[Cites] Oncology. 2005;69(1):35-43 [16088233.001]

[Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]

[Cites] Palliat Med. 2003 Sep;17(6):539-53 [14526888.001]

[Cites] Acta Physiol Scand. 1997 Sep;161(1):81-92 [9381954.001]

[Cites] Oncologist. 2004;9(6):687-95 [15561812.001]

[Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]

[Cites] Cancer. 2007 Nov 1;110(9):1911-28 [17849470.001]

[Cites] Eur Urol. 2007 May;51(5):1202-16 [17182170.001]

[Cites] Clin Biochem. 2007 Mar;40(5-6):383-91 [17316593.001]

[Cites] Bull World Health Organ. 2001;79(4):373-4 [11357217.001]

[Cites] J Clin Pharmacol. 2002 Nov;42(11):1228-36 [12412821.001]

[Cites] J Chemother. 2005 Oct;17(5):555-9 [16323446.001]

[Cites] BJU Int. 2006 Jul;98(1):189-96 [16831167.001]

[Cites] Bone. 2004 Mar;34(3):412-24 [15003789.001]

[Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]

[Cites] Ann Oncol. 2006 Jun;17(6):986-9 [16533874.001]

[Cites] Biochem Biophys Res Commun. 2007 Aug 17;360(1):199-204 [17592728.001]

[Cites] Int J Cancer. 2003 Feb 20;103(5):642-6 [12494472.001]

[Cites] J Cell Biochem. 2005 Jun 1;95(3):497-505 [15838876.001]

[Cites] Prostate. 1999 Jun 1;39(4):246-61 [10344214.001]

[Cites] J Pathol. 2004 Jan;202(1):41-9 [14694520.001]

[Cites] J Endocrinol Invest. 2002 Jun;25(6):539-46 [12109626.001]

[Cites] Cancer Treat Rev. 2008 Apr;34(2):183-92 [18061356.001]

[Cites] Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60 [14746813.001]

(PMID = 18461289.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Cystatin C; 0 / Diphosphonates; 0 / Imidazoles; 0 / Interleukin-6; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Breast cancer is a leading cause of cancer-related deaths in women worldwide.

Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 are frequently encountered in breast carcinomas.

The study was conducted on 34 tissue samples obtained from 33 females and 1 male with breast carcinomas and 17 samples obtained from 16 females and 1 male with benign breast lesions.

Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the benign group.

The sensitivity of the investigated markers significantly increased with larger tumor size.

Concerning tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors.

[MeSH-major] Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / genetics. Egypt / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Pathol. 2000 Jan;156(1):183-91 [10623666.001]

[Cites] Diagn Mol Pathol. 2007 Dec;16(4):207-10 [18043283.001]

[Cites] Breast Cancer Res Treat. 2000 Feb;59(3):211-21 [10832591.001]

[Cites] Indian J Exp Biol. 2000 Mar;38(3):225-30 [10927863.001]

[Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]

[Cites] Acta Oncol. 2000;39(3):327-33 [10987229.001]

[Cites] Endocr Relat Cancer. 2000 Sep;7(3):143-64 [11021963.001]

[Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]

[Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]

[Cites] Int J Cancer. 2001 Jul 20;95(4):266-70 [11400121.001]

[Cites] Tumour Biol. 2001 Sep-Oct;22(5):337-44 [11553865.001]

[Cites] Cancer Res. 2002 Mar 1;62(5):1481-8 [11888924.001]

[Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]

[Cites] Cancer. 2003 Feb 1;97(3):690-4 [12548612.001]

[Cites] Br J Cancer. 2004 Apr 19;90(8):1612-9 [15083194.001]

[Cites] J Pathol. 2004 Aug;203(4):918-26 [15258994.001]

[Cites] Am J Clin Pathol. 2004 Aug;122(2):246-55 [15323142.001]

[Cites] Nature. 1986 Feb 27-Mar 5;319(6056):783-4 [3005871.001]

[Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]

[Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]

[Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]

[Cites] Cell Growth Differ. 1993 Jan;4(1):41-7 [8424905.001]

[Cites] Curr Opin Genet Dev. 1995 Feb;5(1):97-104 [7749333.001]

[Cites] J Pathol. 1995 Nov;177(3):225-32 [8551383.001]

[Cites] Oncogene. 1996 Jul 4;13(1):63-72 [8700555.001]

[Cites] Hum Pathol. 1998 Apr;29(4):323-9 [9563780.001]

[Cites] Breast Cancer Res Treat. 1998 May;49(1):35-9 [9694609.001]

[Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]

[Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):100-8 [9739012.001]

[Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]

[Cites] Am J Clin Pathol. 1999 Oct;112(4):459-69 [10510669.001]

[Cites] Cancer. 2005 Mar 1;103(5):900-5 [15643600.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1909-17 [15753390.001]

[Cites] Oncol Rep. 2005 Apr;13(4):633-41 [15756435.001]

[Cites] Histopathology. 2005 Apr;46(4):431-41 [15810955.001]

[Cites] Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61 [15832994.001]

[Cites] Hum Pathol. 2005 Jun;36(6):634-9 [16021569.001]

[Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]

[Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):340-2 [16295419.001]

[Cites] Breast J. 2005 Nov-Dec;11(6):433-9 [16297088.001]

[Cites] Clin Exp Metastasis. 2005;22(6):495-502 [16320112.001]

[Cites] Breast Cancer Res. 2005;7(6):R1058-79 [16457687.001]

[Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]

[Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]

[Cites] Oncologist. 2006 Sep;11(8):857-67 [16951389.001]

[Cites] Int J Oncol. 2006 Oct;29(4):973-80 [16964393.001]

[Cites] Int J Biol Markers. 2006 Jul-Sep;21(3):131-40 [17013794.001]

[Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401 [10743237.001]

(PMID = 19675743.001).

[ISSN] 1612-3174

[Journal-full-title] German medical science : GMS e-journal

[ISO-abbreviation] Ger Med Sci

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2

[Other-IDs] NLM/ PMC2716551

[Keywords] NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The peripheral washout sign was first described in delayed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a small molecular contrast medium in solid lesions of the human breast and liver.

It was found to be 100% specific for malignant lesions and could therefore potentially be used as an additional noninvasive diagnostic tool differentiating malignant from benign lesions.

[MeSH-minor] Animals. Cell Line, Tumor. Male. Rats. Rats, Inbred Strains. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - MRI Scans.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19178675.001).

[ISSN] 1476-5829

[Journal-full-title] Veterinary and comparative oncology

[ISO-abbreviation] Vet Comp Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Contrast Media

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early tumor detection.

RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant tumor: breast cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .

In two patients thrombophlebitis preceded the diagnosis of the malignancy.

Superficial thrombophlebitis may have been associated in four cases (2.9%) with a benign tumor.

CONCLUSIONS: Breast, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.

In case of a thrombophlebitis without a known malignancy a thorough clinical examination with special regard to skin, breast and abdomen is mandatory.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Early Diagnosis. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Ultrasonography, Doppler, Duplex. Venous Insufficiency / complications. Venous Insufficiency / epidemiology. Venous Insufficiency / ultrasonography

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19588305.001).

[ISSN] 0301-1526

[Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten

[ISO-abbreviation] VASA

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from benign disease.

Cytologic diagnosis was available in 32 of 45 focal thyroid FDG uptakes.

In 16 (50%) patients, the tumor was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic tumor from breast and esophagus.

Sixteen were cytologically diagnosed as follicular cell lesions: follicular neoplasm (n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).

There was no significant difference in maximum SUV between benign and malignant nodules.

From 45 patients with diffuse thyroid FDG uptake, presumptive diagnosis of chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.

CONCLUSION: Our data suggest that a cytologic diagnosis of focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15933524.001).

[ISSN] 0023-852X

[Journal-full-title] The Laryngoscope

[ISO-abbreviation] Laryngoscope

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.

The primary objective of this study was to review the ultrasonographic features of BI-RADS category 3 ("probably benign") lesions that eventually proved to be malignant.

Thirty-two (0.8%) of 4000 women with lesions that were initially classified as "probably benign" proved to be malignant and formed the study group.

There was no statistical difference in the mean age, mean size of lesions, or tumor stage between patients who underwent early biopsy (n = 19) or biopsy after 6 months (n = 13).

[MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Ultrasonography, Mammary / statistics & numerical data

[MeSH-minor] Adult. Aged. Female. Humans. Korea / epidemiology. Male. Middle Aged. Prevalence. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - Biopsy.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

(PMID = 20350681.001).

[ISSN] 1879-291X

[Journal-full-title] Ultrasound in medicine & biology

[ISO-abbreviation] Ultrasound Med Biol

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Trichoblastomas are rare, benign tumors of the appendix in human skin.

This mutation at codon 1,315 represents an already described PTCH germline polymorphism and results in a heterozygous Pro to Leu substitution in the tumor.

The Pro/Leu polymorphism in germline is associated with a higher risk for breast cancer, but a potential contribution to the tumorigenesis of trichoblastoma is unknown.

The genetic basis of this rare appendageal tumor remains elusive.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17597182.001).

[ISSN] 0046-8177

[Journal-full-title] Human pathology

[ISO-abbreviation] Hum. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This damage leads to mutations that can initiate breast and prostate cancer.

To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed.

RESULTS: 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5).

[MeSH-major] Biomarkers, Tumor / urine. DNA Adducts / urine. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / urine

[MeSH-minor] Antibodies, Monoclonal. Early Diagnosis. Electrophoresis, Capillary. Estradiol / analogs & derivatives. Estradiol / chemistry. Estradiol / immunology. Estradiol / urine. Estrogens, Catechol. Humans. Hydroxyestrones / chemistry. Hydroxyestrones / immunology. Hydroxyestrones / urine. Male. Risk Factors

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ESTRADIOL .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2006 Wiley-Liss, Inc.

(PMID = 16894534.001).

[ISSN] 0270-4137

[Journal-full-title] The Prostate

[ISO-abbreviation] Prostate

[Language] eng

[Grant] United States / PHS HHS / / 1 P20 RP15563; United States / NCI NIH HHS / CA / 2P01 CA49210-12

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / DNA Adducts; 0 / Estrogens, Catechol; 0 / Hydroxyestrones; 3131-23-5 / 4-hydroxyestrone; 4TI98Z838E / Estradiol; C3ZO03450E / 4-hydroxyestradiol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM).

In PCa patients, cathepsin K concentrations did not significantly differ from those measured in sex matched HS or in patients with benign prostatic hyperplasia (BPH).

[MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / secondary. Cathepsins / blood. Cystatins / blood

[MeSH-minor] Aged. Aged, 80 and over. Bone Density Conservation Agents / pharmacology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Case-Control Studies. Cathepsin K. Cystatin C. Diphosphonates / pharmacology. Disease Progression. Drug Monitoring / methods. Enzyme-Linked Immunosorbent Assay. Female. Humans. Imidazoles / pharmacology. Male. Middle Aged. Osteoporosis / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. ROC Curve

Genetic Alliance. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Bone Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17728092.001).

[ISSN] 0753-3322

[Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie

[ISO-abbreviation] Biomed. Pharmacother.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Consumption of lycopene, a carotenoid without provitamin A activity, has been associated with a lower risk of prostate and breast cancer.

The effects of grapefruit-derived and commercial lycopene and lutein preparations on androgen independent cultured malignant type II tumor cells [Dunning R3327AT3 or AT3 cells (androgen-responsive, slow-growing tumor cells with well developed epithelium and stroma)] were compared to their benign parent type I tumor epithelial cells (DTE).

No such effect was observed when benign DTE cells were examined, demonstrating selective inhibition of extremely malignant AT3 prostate cancer cells relative to their benign parent.

[MeSH-minor] Animals. Chromatography, High Pressure Liquid. Citrus paradisi. Dose-Response Relationship, Drug. Humans. Male. Rats. Time Factors. Tumor Cells, Cultured

MedlinePlus Health Information. consumer health - Antioxidants.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17640163.001).

[ISSN] 0163-5581

[Journal-full-title] Nutrition and cancer

[ISO-abbreviation] Nutr Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antioxidants; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene; X72A60C9MT / Lutein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including breast myoepithelial cells.

In neoplastic myoepithelial cells, CD10 expression was found in 25.71% of benign and 32.43% of malignant neoplasms.

The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19752720.001).

[ISSN] 1533-4058

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A large benign vascular neoplasm of the male breast. A case report and review of the literature.

Breast hemangiomas are extremely rare neoplasms in the male population.

We report a case of a 77-year old man with a breast hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.

The final histological diagnosis was hemangioma of the breast, 6 cm in the largest diameter.

To our knowledge, this is the largest benign vascular breast neoplasm in a male patient reported up to date.

The rarity of the lesion and its differential diagnosis from angiosarcoma are discussed while the problems encountered in the correct diagnosis and classification of this tumor are also presented.

The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the breast is emphasized.

[MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis

[MeSH-minor] Aged. Humans. Male. Mastectomy, Segmental

MedlinePlus Health Information. consumer health - Birthmarks.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8 [16398236.001]

(PMID = 16122203.001).

[ISSN] 0392-2936

[Journal-full-title] European journal of gynaecological oncology

[ISO-abbreviation] Eur. J. Gynaecol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Italy

[Number-of-references] 10

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVES: To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for the diagnosis of malignant effusions.

DESIGN AND METHODS: Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103 benign effusions.

Thresholds of these tumor markers were chosen for a diagnostic specificity of >or=99%.

RESULTS: Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of breast and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6.

Only 1 patient with breast adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point.

[MeSH-major] Biomarkers, Tumor / analysis. Pleural Effusion, Malignant / diagnosis. Receptor, ErbB-2 / analysis

[MeSH-minor] Adenocarcinoma / diagnosis. Aged. Breast Neoplasms / diagnosis. Carcinoembryonic Antigen / analysis. False Negative Reactions. Humans. Likelihood Functions. Lung Neoplasms / diagnosis. Male. Middle Aged. Mucin-1 / analysis. Pleural Effusion / chemistry. Pleural Effusion / diagnosis. Sensitivity and Specificity

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15925354.001).

[ISSN] 0009-9120

[Journal-full-title] Clinical biochemistry

[ISO-abbreviation] Clin. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; EC 2.7.10.1 / Receptor, ErbB-2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary tumor diagnosis or during follow-up.

The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma, breast cancer, gastric cancer, and melanoma.

Two patients had no history of a primary tumor.

The male/female ratio was 1.9:1.

The mean tumor size was 4.3 cm (range 1.5 to 9).

The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of benign pathologic features (35.3%).

[MeSH-minor] Adult. Female. Humans. Incidental Findings. Male. Middle Aged

MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17445640.001).

[ISSN] 1527-9995

[Journal-full-title] Urology

[ISO-abbreviation] Urology

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

Genetic Alliance. consumer health - Prostate cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

COS Scholar Universe. author profiles.

Biospecimen Research Database. Biospecimen Research Database .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]

[Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]

[Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]

[Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]

[Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]

[Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]

[Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]

[Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]

[Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]

[Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]

[Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]

[Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]

[Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]

[Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]

[Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]

[Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]

[Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]

[Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]

[Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]

[Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]

[Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]

[Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]

[Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]

[Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]

[Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]

[Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]

[Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]

[Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]

[CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]

[CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]

(PMID = 17981926.001).

[ISSN] 0009-9147

[Journal-full-title] Clinical chemistry

[ISO-abbreviation] Clin. Chem.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PTEN hamartoma tumor syndromes.

The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN.

These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ.

Cowden syndrome (CS), the prototypic PHTS syndrome, is associated with increased susceptibility to breast, thyroid, and endometrial cancer.

[MeSH-minor] Cell Movement. Cell Proliferation. Cell Survival. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 10 / metabolism. Female. Humans. Male. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinases / genetics. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. TOR Serine-Threonine Kinases

Genetics Home Reference. consumer health - Bannayan-Riley-Ruvalcaba syndrome.

Genetics Home Reference. consumer health - Cowden syndrome.

Genetics Home Reference. consumer health - PTEN gene.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. OMIM: Data: Gene Annotation .

SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18781191.001).

[ISSN] 1018-4813

[Journal-full-title] European journal of human genetics : EJHG

[ISO-abbreviation] Eur. J. Hum. Genet.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase

[Number-of-references] 77

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of tumor-specific CD8(+) T cells in patients with breast and head and neck cancer.

We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.

EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.

We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.

Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.

[MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism. Male. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15746055.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P50 CA 090440

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.

S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.

S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.

Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.

We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.

[MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood

[MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16142366.001).

[ISSN] 1021-335X

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].

BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.

Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.

This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.

METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).

Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.

RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.

Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).

CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.

The detection may help to select proper therapy and predict prognosis of breast cancer patients.

[MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis

[MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

Genetic Alliance. consumer health - Bone Cancer.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15946491.001).

[Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer

[ISO-abbreviation] Ai Zheng

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.

Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.

The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.

[MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology

[MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15809729.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.

This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.

Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).

A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.

AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).

AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.

This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.

It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16082251.001).

[ISSN] 1541-2016

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Giant myofibroblastoma of breast: a case report.

Myofibroblastoma of the breast is a very rare benign neoplasm usually seen in elderly male and is of very small size.

A 40 year old nulliparous woman was admitted with chief complain of massive enlargement of left breast.

The case was clinically diagnosed as Phyllodes tumor Left mastectomy was done.

The tumor was histopathologically and immunohistochemically diagnosed as Myofibroblastoma.

[MeSH-major] Breast Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17883145.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in breast and prostate cancers and is considered as a tumor suppressor gene.

On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a tumor suppressor gene.

The studies of maspin expression in thyroid neoplasia, the focus of this study, are limited.

We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid neoplasia.

MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different benign and malignant thyroid lesions.

There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and tumor stage.

On the other hand, it was statistically significant as regards tumor multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.

[MeSH-major] Carcinoma, Papillary / diagnosis. Serpins / analysis. Thyroid Neoplasms / diagnosis

[MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Thyroid Gland / chemistry

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17671538.001).

[ISSN] 1110-0362

[Journal-full-title] Journal of the Egyptian National Cancer Institute

[ISO-abbreviation] J Egypt Natl Canc Inst

[Language] eng

[Publication-type] Journal Article

[Publication-country] Egypt

[Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The tumor cells expressed a T-phenotype (CD3+, CD20-) and were CD30-, CD4-, and CD8-negative.

A diagnosis of localized pagetoid reticulosis (Woringer-Kolopp disease) with possible large cell transformation was proposed.

Reevaluation of the skin lesion and of a tonsil specimen previously interpreted as benign hyperplasia showed features consistent with those observed in the lymph node.

[MeSH-major] Breast Neoplasms, Male / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nipples / pathology. Paget's Disease, Mammary / pathology

[MeSH-minor] Adult. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD7 / analysis. Fatal Outcome. Humans. Hyperplasia. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Palatine Tonsil / pathology. T-Lymphocytes / pathology

MedlinePlus Health Information. consumer health - Lymphatic Diseases.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17667175.001).

[ISSN] 0193-1091

[Journal-full-title] The American Journal of dermatopathology

[ISO-abbreviation] Am J Dermatopathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD7

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A granular cell tumor (GCT) is relatively uncommon and objectively diagnosed with neural markers on immunohistochemistry (IHC).

Herein, we present morphologic spectrum of 12 GCTs of soft tissues and skin, including 10 benign and 2 malignant subtypes with an optimal diagnostic IHC panel.

Six cases occurred in soft tissues and skin of extremities, 4 in the breast soft tissues, and 1 case each in the back and preauricular region, respectively.

On histopathology, all cases invariably revealed a nonencapsulated infiltrating tumor comprising groups and nests of granular cells with vesicular nuclei.

Immunohistochemistry in 10 cases (83.3%) showed diffuse S-100 positivity in all 7 benign and 2 malignant cases: cytoplasmic CD68 positivity (all 10 cases) and membranous vimentin staining (all 4 cases).

A GCT is a discrete tumor entity and can be identified from other granular lesions by its proximity to nerves and objective identification with diffuse S-100 positivity, CD68 positivity, and membranous vimentin positivity that form an optimal IHC panel in limited resource settings, irrespective of benign or malignant types.

[MeSH-major] Cancer Care Facilities. Granular Cell Tumor / pathology. Referral and Consultation. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology

[MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Child. Female. Humans. Male. Middle Aged. S100 Proteins / metabolism. Vimentin / metabolism. Young Adult

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20471560.001).

[ISSN] 1532-8198

[Journal-full-title] Annals of diagnostic pathology

[ISO-abbreviation] Ann Diagn Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / S100 Proteins; 0 / Vimentin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: A retrospective study was conducted on all pediatric brain and spinal cord tumor patients operated in a single center from 1999 to 2009.

Details of preoperative treatment, diagnosis and clinical status, postoperative diagnosis, early and late outcomes, progression-free survival and overall survival, and parental satisfaction were reviewed.

In ten cases, radical removal of the tumor resulted in a change in histological diagnosis, usually from a presumed diagnosis of malignancy to a more benign variety (n = 6).

[MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Treatment Outcome

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Childs Nerv Syst. 2010 Sep;26(9):1227-8 [20574741.001]

[ErratumIn] Childs Nerv Syst. 2010 Dec;26(12):1833. Charles, Teo [corrected to Teo, Charles]; Morgan, Broggi [corrected to Broggi, Morgan]

[Cites] Curr Neurol Neurosci Rep. 2001 Mar;1(2):137-43 [11898509.001]

[Cites] Breast J. 2004 Sep-Oct;10(5):469-72 [15327510.001]

[Cites] BMJ. 1996 Jan 20;312(7024):145-8 [8563532.001]

[Cites] J Neurooncol. 2009 May;92(3):275-82 [19357955.001]

[Cites] Breast. 2006 Feb;15(1):119-22 [16473745.001]

[Cites] Neuro Oncol. 2005 Jan;7(1):49-63 [15701282.001]

[Cites] BMJ. 1996 May 4;312(7039):1155-6 [8620140.001]

[Cites] Br J Cancer. 2006 Oct 23;95(8):979-85 [17047646.001]

[Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]

[Cites] Breast J. 2003 Jan-Feb;9(1):60-3 [12558678.001]

[Cites] Med Pediatr Oncol. 2001 Feb;36(2):274-82 [11452935.001]

[Cites] Curr Probl Pediatr Adolesc Health Care. 2005 Jul;35(6):230-45 [15956960.001]

[Cites] Neurosurgery. 2004 Mar;54(3):553-63; discussion 563-5 [15028128.001]

[Cites] Cancer. 1978 Jan;41(1):29-35 [626937.001]

[Cites] Acta Neurochir (Wien). 2009 Feb;151(2):109-12 [19194651.001]

[Cites] Oncology (Williston Park). 2004 Sep;18(10):1263-8; discussion 1268-70, 1275 [15526830.001]

[Cites] Eur J Cancer. 2006 Oct;42(15):2480-91 [16904313.001]

[Cites] Surg Clin North Am. 2000 Apr;80(2):505-33 [10836005.001]

[Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]

[Cites] Pediatr Clin North Am. 1985 Jun;32(3):633-51 [3889800.001]

[Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]

[Cites] Oncology (Williston Park). 2004 Nov;18(13):1649-61; discussion 1662, 1665-6, 1668 [15648297.001]

(PMID = 20563727.001).

[ISSN] 1433-0350

[Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

[ISO-abbreviation] Childs Nerv Syst

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this cross-sectional study, a total of 62 cases were examined, including 43 patients with PTCs and 19 with benign nodular goiters.

In logistic regression analysis, P2X7 receptor expression, tumor size, and capsular infiltration were predictors for lymph node metastasis (P=0.001).

[MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Predictive Value of Tests. Prognosis

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pharmacol Rev. 2006 Mar;58(1):58-86 [16507883.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 [16916931.001]

[Cites] Endocr Rev. 2007 Dec;28(7):742-62 [17940185.001]

[Cites] Purinergic Signal. 2009 Sep;5(3):351-68 [19399640.001]

[Cites] Thyroid. 2009 Jan;19(1):21-5 [19072670.001]

[Cites] Eur J Cancer. 2001 Jun;37(9):1104-10 [11378340.001]

[Cites] J Endocrinol Invest. 2002 Dec;25(11):959-66 [12553555.001]

[Cites] Cancer Lett. 2010 Sep 1;295(1):110-23 [20236757.001]

[Cites] World J Surg. 2007 Nov;31(11):2085-91 [17885787.001]

[Cites] Endocrinology. 2008 Jan;149(1):389-96 [17947359.001]

[Cites] J Biol Chem. 2009 Apr 10;284(15):10120-8 [19204004.001]

[Cites] J Immunol. 2006 Apr 1;176(7):3877-83 [16547218.001]

[Cites] Histopathology. 2004 Mar;44(3):206-15 [14987223.001]

[Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):695-8 [19017759.001]

[Cites] J Biol Chem. 2009 Dec 11;284(50):34553-60 [19854829.001]

[Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]

[Cites] Apoptosis. 2001 Aug;6(4):253-61 [11445667.001]

[Cites] Endocrinology. 2005 Jul;146(7):3172-8 [15790728.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]

[Cites] Nature. 2009 Aug 20;460(7258):1035-9 [19626005.001]

[Cites] J Biol Chem. 2001 Apr 6;276(14):11135-42 [11150303.001]

[Cites] Exp Cell Res. 2002 Oct 1;279(2):277-90 [12243753.001]

[Cites] Ann Surg Oncol. 2008 May;15(5):1518-22 [18324441.001]

[Cites] Biochem Pharmacol. 2009 Nov 1;78(9):1115-26 [19540829.001]

[Cites] Ann Diagn Pathol. 2007 Aug;11(4):235-40 [17630106.001]

[Cites] Hum Immunol. 2010 Aug;71(8):818-25 [20493226.001]

[Cites] Cancer Immunol Immunother. 2004 Sep;53(9):770-6 [15138717.001]

[Cites] Breast Cancer Res Treat. 2004 Jan;83(1):1-10 [14997049.001]

[Cites] Mol Biol Rep. 2010 Apr;37(4):2037-42 [19649722.001]

[Cites] Exp Mol Pathol. 2004 Jun;76(3):253-9 [15126108.001]

[Cites] EMBO Rep. 2006 Oct;7(10):988-94 [17016456.001]

[Cites] Curr Cancer Drug Targets. 2007 Dec;7(8):785-94 [18220537.001]

[Cites] Purinergic Signal. 2009 Jun;5(2):251-6 [19263244.001]

[Cites] Nephrol Dial Transplant. 2007 Feb;22(2):386-95 [17040997.001]

[Cites] Cancer Res. 2006 Jan 15;66(2):907-14 [16424024.001]

[Cites] Endocr Pathol. 2010 Sep;21(3):149-53 [20506003.001]

[Cites] Science. 1996 May 3;272(5262):735-8 [8614837.001]

[Cites] J Neurochem. 2000 Sep;75(3):965-72 [10936177.001]

[Cites] Indian J Cancer. 2010 Apr-Jun;47(2):206-16 [20448388.001]

(PMID = 20972735.001).

[ISSN] 1559-0100

[Journal-full-title] Endocrine

[ISO-abbreviation] Endocrine

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Purinergic P2X7; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Six patients were male and five were female.

Two lesions each arose on the tongue, upper back and popliteal fossa, and one each on the buccal submucosa, shoulder, breast, lateral chest and sole.

The presented tumor was an early one because of the shortest duration and the smallest size in Japan.

Recent criteria for a benign mesenchymoma including a chondrolipoma were also described.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16620227.001).

[ISSN] 0385-2407

[Journal-full-title] The Journal of dermatology

[ISO-abbreviation] J. Dermatol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Japan

[Number-of-references] 18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.

PURPOSE: Because TRAIL (tumor necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer.

Our recent studies suggest that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells.

MATERIALS AND METHODS: Paraffin embedded prostate tissues of 44 patients with benign prostatic hyperplasia, 28 with organ confined prostate carcinoma and 26 with advanced prostate carcinoma were analyzed using immunohistochemical staining procedures.

RESULTS: Significant levels of TRAIL-R4 decoy receptor expression were detected in patients with benign prostatic hyperplasia, and organ confined and advanced prostate carcinoma.

All TRAIL markers tested appear to be valuable markers for separating patients with benign prostatic hyperplasia from patients with organ confined prostate carcinoma or advanced prostate carcinoma.

[MeSH-minor] Humans. Immunohistochemistry. Male

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17162091.001).

[ISSN] 0022-5347

[Journal-full-title] The Journal of urology

[ISO-abbreviation] J. Urol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report].

[Transliterated title] Tumeur desmoïde du sein chez l'homme dans le cadre d'un syndrome de Gardner. A propos d'un cas.

Fibromatosis (Desmoid tumor) of the male breast is an exceptional location.

We present a case of such a tumor, in the context of Gardner's syndrome.

A palpable mass was discovered in the right breast of a 52 years old man, with a history of rectocolic adenomatous polyposis.

Mammography ant thoracic CT scan showed a stellar tumor, mimicking a breast cancer.

Treatment consisted of wide excision and histology revealed a desmoid tumor.

Desmoid tumors of the breast are benign lesions; they should be widely excised because of a high risk of recurrence.

Coloscopy is indicated in the presence of mammary fibromatosis, to look for associated multiple polyps, confirming the diagnosis of Gardner's syndrome.

[MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Fibromatosis, Aggressive / pathology. Fibromatosis, Aggressive / surgery. Gardner Syndrome / complications

[MeSH-minor] Colonoscopy. Humans. Male. Middle Aged. Risk Factors. Tomography, X-Ray Computed

Genetic Alliance. consumer health - Desmoid Tumor.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15664376.001).

[ISSN] 0003-3944

[Journal-full-title] Annales de chirurgie

[ISO-abbreviation] Ann Chir

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.

RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).

Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.

Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.

Genetic Alliance. consumer health - invasive ductal carcinoma.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20701077.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Frequency of breast cancer among Sudanese patients with breast palpable lumps.

BACKGROUND: Breast cancer mortality is high in Sudan and most patients are detected at later stages of the disease due to the lack of awareness and absence of screening programs.

This study aimed to determine the pattern and frequency of breast cancer among patients presenting with palpable breast lumps within one year duration.

METHODS AND MATERIALS: We obtained information (patient's personal data) and Fine-Needle Aspiration (FNA) materials, for occurrence of 200 breast lesions in patients.

RESULTS: The diagnoses of the 200 breast lesions were as follows: 68 (34%) were malignant, 56 cases (28%) were fibroadenoma, 23 cases (11.5%) were fibrocystic change, 22 cases (11%) were inflammatory lesions (including mastitis and abscess formation), 12 cases (6%) were benign cysts and the remaining 19 patients (9.5%) were with lactation changes (8 cases), lipoma (6 cases), gynecomastia (3 cases) and phyllodes tumor (2 cases).

CONCLUSIONS: The frequency of advanced breast cancer among patients with breast lesions is high, in this subset of patients, which signals the urgency for implementation of breast screening programs.

[MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology

[MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast Diseases / diagnosis. Breast Diseases / epidemiology. Female. Humans. Male. Middle Aged. Sudan / epidemiology. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20071785.001).

[ISSN] 1998-4774

[Journal-full-title] Indian journal of cancer

[ISO-abbreviation] Indian J Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.

[MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology

[MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

MedlinePlus Health Information. consumer health - Thymus Cancer.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]

[Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]

[Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]

[Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]

[Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]

[Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]

[Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]

[Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]

[Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]

[Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]

[Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]

[Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]

[Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]

[Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]

[Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]

[Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]

[Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]

[Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]

[Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]

[Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]

[Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]

[Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]

[Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]

[Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]

[Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]

[Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]

[Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]

[Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]

[Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]

[Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]

[Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]

[Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]

[Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]

[Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]

[Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]

[Cites] Differentiation. 1983;23(3):256-69 [6189757.001]

[Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]

[Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]

[Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]

[Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]

[Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]

[Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]

[Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]

[Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]

[Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]

[Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]

[Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]

[Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]

[Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]

[Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]

[Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]

[Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]

[Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]

[Cites] Thymus. 1987;9(2):95-121 [3296336.001]

[Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]

[Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]

[Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]

[Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]

[Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]

[Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]

[Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]

[Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]

[Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]

[Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]

[Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]

[Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]

[Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]

[Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]

[Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]

[Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]

[Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]

[Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]

[Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]

[Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]

[Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]

[Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]

[Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]

[Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]

[Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]

[Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]

[Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]

[Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]

[Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]

[Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]

(PMID = 16309545.001).

[ISSN] 0959-9673

[Journal-full-title] International journal of experimental pathology

[ISO-abbreviation] Int J Exp Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase

[Other-IDs] NLM/ PMC2517450

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microwave tomography in the context of complex breast cancer imaging.

The notion of applying microwave imaging to breast cancer imaging has been studied at various levels by numerous scientists.

The earliest appeal of this concept related to the presumably high property contrast between benign and malignant tissue that was unique to the breast.

Subsequent published studies have shown that this assumption was overly simplistic and that the tissue property heterogeneity is considerable within the breast.

As we have expanded the clinical use of our microwave tomographic system, we are now using this approach to monitor tumor progressions during neoadjuvant chemotherapy.

In these cases, while we can still characterize and track the tumor progression, we have observed a new phenomenon.

Very often these cancer patients exhibit skin thickening near the tumor site.

Our images have reconstructed elevated dielectric properties along the breast surface associated with the accompanying edema.

These observations further add to the complex nature of breast dielectric properties and the challenges for imaging them using microwave interrogation.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] IEEE Trans Med Imaging. 2001 Feb;20(2):104-16 [11321590.001]

[Cites] J Microw Power. 1981 Jun;16(2):107-19 [7033539.001]

[Cites] Magn Reson Med. 1991 Apr;18(2):371-83 [2046518.001]

[Cites] IEEE Trans Biomed Eng. 1995 Oct;42(10):1017-26 [8582719.001]

[Cites] Breast Cancer Res. 2013;15(2):R35 [23621959.001]

[Cites] Acad Radiol. 2007 Feb;14(2):207-18 [17236994.001]

[Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]

[Cites] Med Phys. 2007 Jun;34(6):2014-23 [17654905.001]

[Cites] Phys Med Biol. 2007 Oct 21;52(20):6093-115 [17921574.001]

[Cites] IEEE Trans Med Imaging. 1999 Jun;18(6):496-507 [10463128.001]

(PMID = 21097245.001).

[ISSN] 1557-170X

[Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference

[ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / P01-CA080139

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS512905; NLM/ PMC3757128